Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shortlist Unveiled For GGB Awards

Contenders Revealed Ahead Of 2 November Ceremony In Frankfurt

Executive Summary

The final shortlist of contenders has been unveiled for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt on 2 November.

You may also be interested in...



Iceland’s Coripharma Moves From Start-Up To Growth

Icelandic out-licensing and contract manufacturing firm Coripharma is moving from the start-up phase to fully-fledged growth, with a particular focus on niche generics and a firm eye on environmental and sustainability aspects, CEO Jónína Guðmundsdóttir tells Generics Bulletin.

Generics Bulletin Editor’s Picks For Q3 2022

Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.

IGBA Joins Fight The Fakes Alliance

As the Fight The Fakes Alliance holds its fifth annual “Fight The Fakes Week,” the IGBA has signed to become a new member of the association as it calls for fresh action to prevent falsified medicines from reaching patients.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel